15.25SEK-1.93%Mkt Cap: 106.59M SEKP/E: —Last update: 2026-05-13
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natu…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B4.28
P/S—
EV/EBITDA-2.08
EV/Revenue—
EPS (TTM)-5.59
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-21.44%
FCF Margin—
Operating CF-36.92M SEK
CapEx (TTM)129.00K SEK
Net Debt/EBITDA0.76
Net Debt-27.39M SEK
Technical
SMA 5014.32 (+6.5%)
SMA 20020.76 (-26.6%)
Beta0.24
S&P 52W Chg24.23%
Avg Vol (30d)6.38K
Avg Vol (10d)1.98K
Technical Indicators
RSI (14)53.9
MACD0.3080
MACD Signal0.2640
MACD Hist.+0.0440
BB Upper16.32 SEK
BB Middle14.93 SEK
BB Lower13.54 SEK
BB Width18.65%
ATR (14)0.7983 SEK
Vol Ratio (20d)0.05x
52W Range
11.6512% of range41.20
52W High41.20 SEK
52W Low11.65 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-147.97%
ROA-122.34%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio5.47
Quick Ratio5.32
Book Value/Sh3.532 SEK
Cash/Share3.881 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateMay 28, 2025
Ownership
Shares Out.7.06M
Float3.56M
Insiders70.41%
Institutions3.79%
Analyst Consensus
Rating—
Target (Mean)75.00 SEK
Target Range75.00 SEK – 75.00 SEK
# Analysts1
Company
Market Cap106.59M SEK
Enterprise Value74.96M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-36.89M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
Last Price15.25 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—